Cytosorbents (CTSO) Gross Margin (2011 - 2026)
Cytosorbents (CTSO) posted Gross Margin of 69.16% for Q1 2026, down 6.15% on a QoQ basis from 73.68% in Q4 2025, and down 197.0% year-over-year from 71.29% in Q1 2025.
Cytosorbents (CTSO) Gross Margin (2011 - 2026) Analysis & Trends
Cytosorbents' Gross Margin history runs 16 years deep, the most recent figure standing at 69.16% for Q1 2026.
- Quarterly Gross Margin fell 197.0% year-over-year to 69.16% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 71.01% (up 245.0% YoY) and the FY2025 annual result came in at 71.48%, up 156.0% from the prior year.
- Gross Margin was 69.16% for Q1 2026 at Cytosorbents, down from 73.68% in the prior quarter.
- Across five years, Gross Margin topped out at 76.46% in Q1 2024 and bottomed at 44.6% in Q3 2022.
- A 5-year average of 65.82% and a median of 68.35% in 2024 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2022 — Gross Margin tumbled 3017 bps — and 2023, when it surged 1904 bps.
- Cytosorbents' Gross Margin stood at 61.31% in 2022, then dropped by 0 bps to 61.27% in 2023, then gained by 12 bps to 68.35% in 2024, then advanced by 8 bps to 73.68% in 2025, then slipped by 6 bps to 69.16% in 2026.
- Business Quant data shows CTSO's Gross Margin at 69.16% in Q1 2026, 73.68% in Q4 2025, and 70.28% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 56.20% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 63.29% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 65.35% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 69.46% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 78.01% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 62.95% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 45.22% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 38.53% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Cytosorbents | 22.58 Mn | 17.78 Mn | 6.13 Mn | 69.16% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 69.16% |
| Dec 31, 2025 | 73.68% |
| Sep 30, 2025 | 70.28% |
| Jun 30, 2025 | 70.85% |
| Mar 31, 2025 | 71.12% |
| Dec 31, 2024 | 68.35% |
| Sep 30, 2024 | 61.02% |
| Jun 30, 2024 | 73.55% |
| Mar 31, 2024 | 76.46% |
| Dec 31, 2023 | 61.27% |
| Sep 30, 2023 | 63.64% |
| Jun 30, 2023 | 63.89% |
| Mar 31, 2023 | 57.73% |
| Dec 31, 2022 | 61.31% |
| Sep 30, 2022 | 44.60% |
| Jun 30, 2022 | 58.21% |
| Mar 31, 2022 | 73.79% |
| Dec 31, 2021 | 71.04% |
| Sep 30, 2021 | 74.77% |
| Jun 30, 2021 | 77.46% |